Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 150

Sort by

Sort Order Select

Journal Articles

How I treat transplant-eligible patients with myelofibrosis

Nicolaus Kröger, Christine Wolschke, Nico Gagelmann

Blood blood.2023021218.

https://doi.org/10.1182/blood.2023021218

Published: 2023

Journal Articles

Impact of TP53 on outcome of patients with myelofibrosis undergoing hematopoietic stem cell transplantation

Nico Gagelmann, Anita Badbaran, Rachel B. Salit, Thomas Schroeder, Carmelo Gurnari, Simona Pagliuca, Victoria Panagiota, Christina Rautenberg, Bruno Cassinat, Felicitas Thol, Christine Wolschke, Marie Robin, Michael Heuser, Marie-Thérèse Rubio, Jaroslaw P. Maciejewski, Hans Christian Reinhardt, Bart L. Scott, Nicolaus Kröger

Blood (2023) 141 (23): 2901–2911.

https://doi.org/10.1182/blood.2023019630

Published: 2023

Includes: Supplemental data

Journal Articles

Gvhd Prophylaxis Incorporating Methotrexate in Allo-HCT for Chronic Myeloid Malignancies and sAML: A Retrospective Analysis from the Cmwp of the EBMT

Blood (2022) 140 (Supplement 1): 900–902.

https://doi.org/10.1182/blood-2022-160121

Published: 2022

Journal Articles

Allogeneic Stem Cell Transplant for Myelodysplastic Syndrome in the New Molecular Era of IPSS-M

Carmelo Gurnari, Nico Gagelmann, Anita Badbaran, Hussein Awada, Danai Dima, Simona Pagliuca, Maud d'Aveni, Enrico Attardi, Raffaella Cerretti, Wolschke Christine, Marie Thérèse Rubio, Jaroslaw P. Maciejewski, Nicolaus Kröger

Blood (2022) 140 (Supplement 1): 10616–10617.

https://doi.org/10.1182/blood-2022-167518

Published: 2022

Journal Articles

Registry Data Indicate a Meaningful Chance for Successful Pregnancies after Allogeneic Stem Cell Transplantation: Results from the German Stem Cell Transplant Registry (DRST)

Katja Sockel, Sandra Frank, Annika Neu, Markus Ditschkowski, Inken Hilgendorf, Mareen Goeckenjan, Friedrich Stoelzel, Jan Moritz Middeke, Nicolaus Kröger, Francis A. Ayuk, Matthias Eder, Wolfgang Bethge, Jürgen Finke, Hartmut Bertz, Guido Kobbe, Martin Kaufmann, Uwe Platzbecker, David Beverungen, Christoph Schmid, Malte von Bonin, Katharina Egger-Heidrich, Lisa Heberling, Karolin Trautmann-Grill, Raphael Teipel, Gesine Bug, Johanna Tischer, Alessia Fraccaroli, Barbara Holler, Daniel Wolff, Thomas Luft, Wolf Roesler, Kerstin Schäfer-Eckart, Sabine Dressler, Christof Scheid, Udo Holtick, Stefan Klein, Igor Wolfgang Blau, Andreas Burchert, Gerald Wulf, Justin Hasenkamp, Rainer Schwerdtfeger, Stephan Kaun, Christoph Wittke, Friederike Wortmann, Helga Neidlinger, Martin Bornhaeuser, Johannes Schetelig, on Behalf of the German Cooperative Transplant Study Group

Blood (2022) 140 (Supplement 1): 10563–10565.

https://doi.org/10.1182/blood-2022-162673

Published: 2022

Journal Articles

Real-World Results of CAR-T Cell Therapy for Large B Cell Lymphoma with CNS Involvement: A GLA/DRST Study

Francis A. Ayuk, Nico Gagelmann, Gerald Wulf, Bastian von Tresckow, Kai Rejeski, Matthias Stelljes, Olaf Penack, Claudia D. Baldus, Nicolaus Kröger, Wolfgang Bethge, Peter Dreger

Blood (2022) 140 (Supplement 1): 10394–10395.

https://doi.org/10.1182/blood-2022-166104

Published: 2022

Journal Articles

Early Hepatotoxicity in Patients with Myelofibrosis after Allogeneic Hematopoietic Cell Transplantation (Allo-HCT)

Blood (2022) 140 (Supplement 1): 7585–7586.

https://doi.org/10.1182/blood-2022-156076

Published: 2022

Journal Articles

Validation of the Transplant Conditioning Intensity (TCI) Score for Allogeneic Hematopoietic Cell Transplantation

Blood (2022) 140 (Supplement 1): 2389–2391.

https://doi.org/10.1182/blood-2022-157890

Published: 2022

Journal Articles

Continuously Improving Outcome over Time after Second Allogeneic Stem Cell Transplantation in Relapsed Acute Myeloid Leukemia - a Retrospective Analysis of 1540 Patients on Behalf of the Acute Leukemia Working Party of EBMT

Ann-Kristin Schmälter, Maud Ngoya, Jürgen Finke, Nicolaus Kröger, Friedrich Stölzel, Matthias Stelljes, Thomas Valerius, Johanna Tischer, Thomas Schroeder, Peter Dreger, Igor Wolfgang Blau, Bipin Savani, Sebastian Giebel, Jordi Esteve, Ali Bazarbachi, Arnon Nagler, Christoph Schmid, Fabio Ciceri, Mohamad Mohty

Blood (2022) 140 (Supplement 1): 4799–4801.

https://doi.org/10.1182/blood-2022-163788

Published: 2022

Journal Articles

Outcomes of Allogeneic Hematopoietic Stem Cell Transplantation from Different Donor Types in Primary Refractory Acute Myeloid Leukemia: A Report from the ALWP of the EBMT

Blood (2022) 140 (Supplement 1): 10613–10615.

https://doi.org/10.1182/blood-2022-165472

Published: 2022

Journal Articles

Allogeneic Hematopoietic Cell Transplantation (Allo-HCT) in Patients with Calr -Mutated Myelofibrosis

Blood (2022) 140 (Supplement 1): 10608–10610.

https://doi.org/10.1182/blood-2022-163048

Published: 2022

Journal Articles

Increased LFS Following Hematopoietic Cell Transplantation As Compared to Conventional Consolidation Therapy in Patients >60 Years with AML in First Complete Remission and a Matched Donor: Results of a Randomized Phase III Study

Blood (2022) 140 (Supplement 1): 2126–2129.

https://doi.org/10.1182/blood-2022-157684

Published: 2022

Journal Articles

Risk Factors Influencing Transplant Outcomes of Adults with Acute Lymphoblastic Leukemia in First Complete Remission: A Retrospective Analysis from the ALWP of the EBMT

Blood (2022) 140 (Supplement 1): 4870–4871.

https://doi.org/10.1182/blood-2022-166081

Published: 2022

Journal Articles

Amsa/ARA-C Followed By TBI 4 Gy or High Dose Chemotherapy Conditioning Regimens in Primary Refractory AML - Significantly Worse Outcomes in Younger Patients Conditioned with 4 Gy TBI

Rama Al Hamed, Myriam Labopin, Wolfgang Bethge, Arnold Ganser, Arne Brecht, Johanna Tischer, Nicolaus Kröger, Donald Bunjes, Hermann Einsele, Mareike Verbeek, Igor Wolfgang Blau, Martin Kaufmann, Eolia Brissot, Ali Bazarbachi, Christoph Schmid, Alexandros Spyridonidis, Arnon Nagler, Fabio Ciceri, Mohamad Mohty

Blood (2022) 140 (Supplement 1): 10455–10457.

https://doi.org/10.1182/blood-2022-170244

Published: 2022

Journal Articles

A Second Haploidentical Stem Cell Transplantation (HAPLO-SCT2) after Relapse from First Haplo-SCT Is Feasible and Produces Results That Are Comparable to Data Reported after Second SCT in an HLA-Matched Setting - a Study on Behalf of the Acute Leukaemia Working Party (ALWP) of the European Society for Blood and Marrow Transplantation (EBMT)

Giuliano Filippini Velazquez, Myriam Labopin, Johanna Tischer, Emanuele Angelucci, Alexander D. Kulagin, Piero Galieni, Arancha Bermúdez, Claude-Eric Bulabois, Nicolaus Kröger, José Luis Díez-Martin, Arnon Nagler, Christoph Schmid, Fabio Ciceri, Mohamad Mohty

Blood (2022) 140 (Supplement 1): 7744–7746.

https://doi.org/10.1182/blood-2022-160229

Published: 2022

Journal Articles

Improved Post-Transplant Outcomes in Recent Years for AML Patients with Intermediate Karyotype, FLT3 -ITD and Wild Type NPM1 : A Report from the EBMT Acute Leukemia Working Party

Ali Bazarbachi, Myriam Labopin, Tobias Gedde-Dahl, Péter Reményi, Edouard Forcade, Nicolaus Kröger, Gerard Socie, Charles Craddock, Jean-Henri Bourhis, Jurjen Versluis, Ibrahim Yakoub-Agha, Urpu Salmenniemi, Jean Elcheikh, Gesine Bug, Jordi Esteve, Arnon Nagler, Fabio Ciceri, Mohamad Mohty

Blood (2022) 140 (Supplement 1): 4897–4898.

https://doi.org/10.1182/blood-2022-165069

Published: 2022

Journal Articles

Organ Complications after CD19 CAR T-Cell Therapy for Large B Cell Lymphoma. a Retrospective Study from the EBMT Transplant Complications and Lymphoma Working Partys

Blood (2022) 140 (Supplement 1): 10413–10415.

https://doi.org/10.1182/blood-2022-169037

Published: 2022

Journal Articles

Artificial Intelligence Methods to Estimate Overall Mortality and Non-Relapse Mortality Following Allogeneic Hematopoietic Cell Transplantation in the Modern Era: An EBMT Transplant Complications Working Party Study

Blood (2022) 140 (Supplement 1): 7734–7737.

https://doi.org/10.1182/blood-2022-168601

Published: 2022

Journal Articles

CTX110 Allogeneic CRISPR-Cas9-Engineered CAR T Cells in Patients (Pts) with Relapsed or Refractory (R/R) Large B-Cell Lymphoma (LBCL): Results from the Phase 1 Dose Escalation Carbon Study

Blood (2022) 140 (Supplement 1): 10303–10306.

https://doi.org/10.1182/blood-2022-166432

Published: 2022

Journal Articles

An Analysis of the Worldwide Utilization of Hematopoietic Stem Cell Transplantation for Acute Myeloid Leukemia

Molly Tokaz, Helen Baldomero, Andrew J Cowan, Wael Saber, Hildegard T. Greinix, Mickey Koh, Nicolaus Kröger, Mohamad Mohty, Sebastian Galeano, Shinichiro Okamoto, Naeem A. Chaudhri, Amado J Karduss, Fabio Ciceri, Vergilio Rensi Colturato, Selim Corbacioglu, Alaa M. Elhaddad, Lisa Force, Cristobal Augusto Frutos Ortiz, Andres Gomez-De Leon, Nada Hamad, Nelson Hamerschlak, Naya He, Aloysius YL Ho, Xiao-Jun Huang, Benjamin Jacobs, Heeje Kim, Minako Iida, Leslie E. Lehmann, Régis Peffault de Latour, Mary-Elizabeth M. Percival, Walid Rasheed, Kirk R. Schultz, Adriana Seber, Bor-Sheng Ko, Anderson Simione, Alok Srivastava, Jeff Szer, William A. Wood, Yoshihisa Kodera, Arnon Nagler, John A Snowden, Daniel J. Weisdorf, Jakob R. Passweg, Marcelo C Pasquini, Anna Sureda, Yoshiko Atsuta, Mahmoud Aljurf, Dietger Niederwieser, Martina Perdomo

Blood (2022) 140 (Supplement 1): 8146–8149.

https://doi.org/10.1182/blood-2022-158338

Published: 2022

NARROW

How I treat transplant-eligible patients with myelofibrosis

Impact of TP53 on outcome of patients with myelofibrosis undergoing hematopoietic stem cell transplantation

Gvhd Prophylaxis Incorporating Methotrexate in Allo-HCT for Chronic Myeloid Malignancies and sAML: A Retrospective Analysis from the Cmwp of the EBMT

Allogeneic Stem Cell Transplant for Myelodysplastic Syndrome in the New Molecular Era of IPSS-M

Registry Data Indicate a Meaningful Chance for Successful Pregnancies after Allogeneic Stem Cell Transplantation: Results from the German Stem Cell Transplant Registry (DRST)

Real-World Results of CAR-T Cell Therapy for Large B Cell Lymphoma with CNS Involvement: A GLA/DRST Study

Early Hepatotoxicity in Patients with Myelofibrosis after Allogeneic Hematopoietic Cell Transplantation (Allo-HCT)

Validation of the Transplant Conditioning Intensity (TCI) Score for Allogeneic Hematopoietic Cell Transplantation

Continuously Improving Outcome over Time after Second Allogeneic Stem Cell Transplantation in Relapsed Acute Myeloid Leukemia - a Retrospective Analysis of 1540 Patients on Behalf of the Acute Leukemia Working Party of EBMT

Outcomes of Allogeneic Hematopoietic Stem Cell Transplantation from Different Donor Types in Primary Refractory Acute Myeloid Leukemia: A Report from the ALWP of the EBMT

Allogeneic Hematopoietic Cell Transplantation (Allo-HCT) in Patients with Calr -Mutated Myelofibrosis

Increased LFS Following Hematopoietic Cell Transplantation As Compared to Conventional Consolidation Therapy in Patients >60 Years with AML in First Complete Remission and a Matched Donor: Results of a Randomized Phase III Study

Risk Factors Influencing Transplant Outcomes of Adults with Acute Lymphoblastic Leukemia in First Complete Remission: A Retrospective Analysis from the ALWP of the EBMT

Amsa/ARA-C Followed By TBI 4 Gy or High Dose Chemotherapy Conditioning Regimens in Primary Refractory AML - Significantly Worse Outcomes in Younger Patients Conditioned with 4 Gy TBI

Improved Post-Transplant Outcomes in Recent Years for AML Patients with Intermediate Karyotype, FLT3 -ITD and Wild Type NPM1 : A Report from the EBMT Acute Leukemia Working Party

Organ Complications after CD19 CAR T-Cell Therapy for Large B Cell Lymphoma. a Retrospective Study from the EBMT Transplant Complications and Lymphoma Working Partys

Artificial Intelligence Methods to Estimate Overall Mortality and Non-Relapse Mortality Following Allogeneic Hematopoietic Cell Transplantation in the Modern Era: An EBMT Transplant Complications Working Party Study

CTX110 Allogeneic CRISPR-Cas9-Engineered CAR T Cells in Patients (Pts) with Relapsed or Refractory (R/R) Large B-Cell Lymphoma (LBCL): Results from the Phase 1 Dose Escalation Carbon Study

An Analysis of the Worldwide Utilization of Hematopoietic Stem Cell Transplantation for Acute Myeloid Leukemia

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only